Please assess the completion status of the following clinical trial:

Trial Title: Lung Function and Patient Preference With QVA149 vs. Tiotropium in COPD Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* signed an Informed Consent Form~* stable COPD according to current guidelines (GOLD 2013)~* airflow limitation indicated by a post-bronchodilator FEV1/FVC ratio of \<0.70 and a post-bronchodilator FEV1 of ≥30% and \<80% of predicted normal values at Visit 2.~* current or ex-smokers who have a smoking history of at least 10 pack years~* Patients on stable tiotropium (18 µg/d) monotherapy for at least 8 weeks before Visit 1~* Symptomatic patients defined as patients with CAT score ≥ 10 at Visit 1 (Screening).~Exclusion Criteria:~* Pregnant or breast feeding mothers~* Patients with conditions contraindicated for treatment~* Patients with a history of clinically significant diseases~* Patients who have a clinically significant renal disease~* Patients with myocardial infarctions less than 6 months prior to study entry~* Patients with recent (less than 1 year) history of NYHA Class III/IV left ventricular failure.~* Patients with narrow-angle glaucoma, symptomatic prostatic hyperplasia or bladder-neck obstruction or urinary retention~* Patients with a history of malignancy of any organ system~* Patients who have had a COPD exacerbation that required treatment with antibiotics, and/or systemic steroids (oral or intravenous) and/or hospitalization in the 6 weeks prior to Screening~* Patients who have had a respiratory tract infection within 6 weeks prior to Screening~* Patients with any history of asthma.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment sequence 1 (Type: EXPERIMENTAL): QVA149 from day 1 to day 28 and tiotropium from day 29 to day 56
- Treatment sequence 2 (Type: EXPERIMENTAL): Tiotropium from day 1 to day 28 and QVA149 from day 29 to day 56

Based on this trial design, predict the completion outcome and termination type (if applicable).